← Back to Search

Diuretic

Hydrochlorothiazide 25 mg for High Blood Pressure

Phase 4
Waitlist Available
Led By Khalid Bashir, MD
Research Sponsored by Creighton University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 weeks
Awards & highlights
Drug Has Already Been Approved
All Individual Drugs Already Approved
No Placebo-Only Group
Approved for 20 Other Conditions
Pivotal Trial

Summary

This will be a randomized, double-blinded, three-period crossover study of platelet activation and aggregation in 30 non-smoking healthy volunteers comparing chlorthalidone (CTD), hydrochlorothiazide (HCTZ), and aspirin (ASA; active control). The study hypothesis is that CTD has different effects on platelet activation and aggregation than HCTZ.

Eligible Conditions
  • High Blood Pressure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in mean fluorescence intensity of PAC-1
Secondary study objectives
Change in CD62P expression
Change in platelet aggregation

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Approved for 20 Other Conditions
This treatment demonstrated efficacy for 20 other conditions.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Hydrochlorothiazide 25 mgExperimental Treatment1 Intervention
Hydrochlorothiazide 25 mg by mouth once daily for 2 weeks
Group II: Chlorthalidone 12.5 mgExperimental Treatment1 Intervention
Chlorthalidone 12.5 mg by mouth once daily for 2 weeks
Group III: Aspirin 81 mgActive Control1 Intervention
Aspirin 81 mg by mouth once daily for 2 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Hydrochlorothiazide
FDA approved

Find a Location

Who is running the clinical trial?

Creighton UniversityLead Sponsor
125 Previous Clinical Trials
25,666 Total Patients Enrolled
Dialysis Clinic, Inc.Industry Sponsor
23 Previous Clinical Trials
11,888 Total Patients Enrolled
Khalid Bashir, MDPrincipal InvestigatorCreighton University
~3 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top